{"id":36492,"date":"2021-10-18T16:40:00","date_gmt":"2021-10-18T14:40:00","guid":{"rendered":"https:\/\/www.ipsen.com\/?post_type=press_release&#038;p=36492"},"modified":"2023-08-31T07:25:55","modified_gmt":"2023-08-31T05:25:55","slug":"ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/","title":{"rendered":"Ipsen adds another program into its pre-clinical R&amp;D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3"},"content":{"rendered":"<ul>\n<li style=\"margin-bottom:3px\">Ipsen obtains an exclusive license to develop, manufacture and commercialize<br \/>\na pre-clinical stage METTL3-inhibitor program<\/li>\n<li style=\"margin-bottom:3px\">Building on recent announcements, this collaboration with Accent Therapeutics reinforces Ipsen\u2019s expansion into hematological malignancies, with a focus on acute myeloid leukemia<\/li>\n<\/ul>\n<p><b>Paris (France), 18 October 2021 \u2013\u00a0<\/b>Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accent\u2019s pre-clinical stage METTL3 program.<\/p>\n<p>Acute myeloid leukemia (AML) is a difficult to treat cancer of the blood and bone marrow, accounting for a third of all new cases of leukemia in the US each year.1\u00a0Globally, the incidence of AML has been increasing year on year across the last 20 years.2\u00a0RNA modifying proteins (RMPs) are an emerging target class that control multiple aspects of RNA biology and represent a new approach for the potential treatment of various cancers. METTL3 is an RMP that has been validated pre-clinically as a novel therapeutic target for AML.1,3\u00a0This collaboration combines Accent\u2019s expertise in RMP-targeting therapeutics with Ipsen\u2019s capabilities and proven track record in Oncology medicine development and commercialization.<\/p>\n<p>Christelle Huguet, Senior Vice President, Head of Research, External Innovation and Early Development, Ipsen, said \u201cOncology is a key focus area for Ipsen as we grow our pipeline. We are delighted to partner with Accent to progress the METTL3 program as we continue our expansion into hematologic oncology. Our teams are steadfast in our commitment to areas of high unmet medical need including rare cancers, so this collaboration is strongly aligned with Ipsen\u2019s mission and strategy for growth.\u201d<\/p>\n<p>Shakti Narayan, Chief Executive Officer of Accent Therapeutics said \u201cThis collaboration blends Ipsen\u2019s commitment to developing and commercializing transformative oncology medicines with Accent\u2019s leading expertise in the field of RNA modification. As we focus on developing our rich pipeline of novel RMP-targeted therapies, we are pleased to entrust our METTL3 program to the innovative team at Ipsen to bring this novel investigational therapy to patients in need.\u201d<\/p>\n<p>Under the agreement, Ipsen will pay up to $446m, comprising upfront payment as well as pre-clinical, clinical, regulatory, and sales-based milestone payments, plus tiered sales royalties ranging from mid-single digits to low-double digits.<\/p>\n<ol>\n<li style=\"margin-bottom:3px\">American Cancer Society. Key statistics for Acute Myeloid Leukemia.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_BEeumDFikVEKEqJGvI2nUC2MNvKCHSXtzMseMgb0a7008AEN6GutCGX8s7tNQdgt6tLI9G-HHbLvHRYrw7GkF_Ki9aN_klU47Ywy-D_VdHZ4Hirb_dBlvTQtSnR3YGQ52Plyu7ay6cARRQT5Rj7GvRzIqAAG_NdDt-TERs_e6pO-V-SEZ51xrKq1O4PX6AFgUdywKelOsLzTNvAK-nLagpnjR5yucWqclvFru6cIsWSwB3mHiKqo5LpHpi1ExBD\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>https:\/\/www.cancer.org\/cancer\/acute-myeloid-leukemia\/about\/key-statistics.html<\/b><\/a><\/li>\n<li style=\"margin-bottom:3px\">Yin Dong, Oumin Shi, Quanxiang Zeng, Xiaoquin Lu, Wei Wang, Yong Li, Qi Wang, Yong Li and Qi Wang, Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Experimental Hematology &amp; Oncology 9, Article number 14. 2020<\/li>\n<li style=\"margin-bottom:3px\">Shane M Buker, Zachary A Gurard-Levin, Benjamin D Wheeler, Michael D Scholle, April W Case, Jeffrey L Hirsch, Scott Ribich, Robert A Copeland, P Ann Boriack-Sjodin. A Mass Spectrometric Assay of METTL3\/METTL14 Methyltransferase Activity. SLAS Discov. 2020 Apr;25(4):361-371. Epub 2019 Oct 4.<\/li>\n<\/ol>\n<p id=\"gnw_attachments_section-header\">\n    <strong>Attachment<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=JyHvTFzV7iIs6IRFwC8rwr-1hv-r1Nb6lS_y_S_s67-ydWdS10KcyGVtTCd9Gt-D2K8PeMmZuJb8Ip1D6Yqf1mpHxZZKx1lhgOibtQhCTc8PebsB5FyWljoM72T1O_ePnAcmmOFffCPotF-2J8QYAJQW9AVlEuVM2Q-B-vgY_u3eKdKyGdFUH5n_7eVAufRiuVYc-ueUHmGgo4c3PcuzRQ==\" title=\"Ipsen-Accent-collaboration-18-October-2021\" rel=\"nofollow noopener\">Ipsen-Accent-collaboration-18-October-2021<\/a><\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1763,1767],"tags":[],"class_list":["post-36492","press_release","type-press_release","status-publish","hentry","category-corporate-pressrelease","category-oncology-pressrelease","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen adds another program into its pre-clinical R&amp;D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen adds another program into its pre-clinical R&amp;D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-31T05:25:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\"},\"headline\":\"Ipsen adds another program into its pre-clinical R&amp;D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3\",\"datePublished\":\"2021-10-18T14:40:00+00:00\",\"dateModified\":\"2023-08-31T05:25:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/\"},\"wordCount\":488,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"articleSection\":[\"Corporate\",\"Oncology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/\",\"url\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/\",\"name\":\"Ipsen adds another program into its pre-clinical R&amp;D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2021-10-18T14:40:00+00:00\",\"dateModified\":\"2023-08-31T05:25:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen adds another program into its pre-clinical R&amp;D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/#website\",\"url\":\"https:\/\/www.ipsen.com\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen adds another program into its pre-clinical R&amp;D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/","og_locale":"en_US","og_type":"article","og_title":"Ipsen adds another program into its pre-clinical R&amp;D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3","og_url":"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/","og_site_name":"Global","article_modified_time":"2023-08-31T05:25:55+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0"},"headline":"Ipsen adds another program into its pre-clinical R&amp;D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3","datePublished":"2021-10-18T14:40:00+00:00","dateModified":"2023-08-31T05:25:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/"},"wordCount":488,"publisher":{"@id":"https:\/\/www.ipsen.com\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","articleSection":["Corporate","Oncology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/","url":"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/","name":"Ipsen adds another program into its pre-clinical R&amp;D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3","isPartOf":{"@id":"https:\/\/www.ipsen.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2021-10-18T14:40:00+00:00","dateModified":"2023-08-31T05:25:55+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MTcwYWZhZTktMDAwZC00NjM0LWJiNjQtNGJlNzY1NjUzNGE3LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/"},{"@type":"ListItem","position":2,"name":"Ipsen adds another program into its pre-clinical R&amp;D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/#website","url":"https:\/\/www.ipsen.com\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/press_release\/36492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":2,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/press_release\/36492\/revisions"}],"predecessor-version":[{"id":36494,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/press_release\/36492\/revisions\/36494"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/media?parent=36492"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/categories?post=36492"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/tags?post=36492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}